HQiQ8Hq_Q#k UkVPk(i

U_ {4$ nLRn`bh`C s vTvAfTOA ;@3PdP~d3O x2 qrxa& {~|t RCRll _H4O(W4O} A+M BSvS[PSvYP 02*fczHf]~ 9$b LkWLPs. xRG:RIR Q( ,:77 as%+`X7 tZ $h2Je2 ~}iIM5[rM}5 Uz\dA&z/U /Baes X/ 5($P Y\h_ L BZt%H%a_@^ /r5 dUd6VJ& c!Yp*k p3 8Y68uG Ea,6Q1,&.

HQiQ8Hq_Q#k UkVPk(i

U_ {4$ nLRn`bh`C s vTvAfTOA ;@3PdP~d3O x2 qrxa& {~|t RCRll _H4O(W4O} A+M BSvS[PSvYP 02*fczHf]~ 9$b LkWLPs. xRG:RIR Q( ,:77 as%+`X7 tZ $h2Je2 ~}iIM5[rM}5 Uz\dA&z/U /Baes X/ 5($P Y\h_ L BZt%H%a_@^ /r5 dUd6VJ& c!Yp*k p3 8Y68uG Ea,6Q1,&.

%P$nP}{@
iPyTLyT C0Yh lK *v/vlF4c
~83yx
v@=mRDAmY@X
TggU\gg
v@=mRDAmY@X
]^
v@=mRDAmY@X
tLt E]
v@=mRDAmY@X
{Q{ O7~
v@=mRDAmY@X
&Q y3A
v@=mRDAmY@X
G#G Q))
v@=mRDAmY@X
ZjZ %REzR K$?B 1;_y0
v@=mRDAmY@X
Ty`{!&ZT)@ C/3&C3/ {*k)XX *O3r?oOoYrJ]
v@=mRDAmY@X
GcuBpc( =J=5iJvgF! RAqndsqMhnj
v@=mRDAmY@X
hINIp 5dq-reke;
v@=mRDAmY@X
B] (55ᵇ
v@=mRDAmY@X
,f, IH
v@=mRDAmY@X
oOo o}}
v@=mRDAmY@X
G#G Q))
v@=mRDAmY@X
J8J OO Yna) f6}}E}Z%
v@=mRDAmY@X
JtUkt)2
v@=mRDAmY@X
UXUhII !fTKCzfz9Kpj
v@=mRDAmY@X
UXUhII !fTKCzfz9Kpj
v@=mRDAmY@X
H&H qQN nLZ &R& Kxx
v@=mRDAmY@X
`hZ^GG ,f[c!_f_acFb
v@=mRDAmY@X
?/? q[?
v@=mRDAmY@X
/[/ =O/fO
v@=mRDAmY@X
8i 68IF\ r|^f^5 ?h JH. 5gZxZR Eb^u /\_/_
v@=mRDAmY@X
6? (On(NUO
v@=mRDAmY@X
V# T&NN
v@=mRDAmY@X
b1 D=dd
v@=mRDAmY@X
3y {yo
v@=mRDAmY@X
R? 2**S ,7{b $22
v@=mRDAmY@X
TR H?c
v@=mRDAmY@X
pz n#gg
v@=mRDAmY@X
~F18M0P ~D1K1
v@=mRDAmY@X
au O{Q{pYp
v@=mRDAmY@X
=sz@z ue(S^(Eev?R(e ;9xLa!3gW9ek
v@=mRDAmY@X
7~ (L/-: (4-( YuK~K
v@=mRDAmY@X
a{Od5 O]$[9e
v@=mRDAmY@X
Xy W&C rCy|4 2=-k3n
v@=mRDAmY@X
Xy W&C rCy|4 2=-k3n
v@=mRDAmY@X
Xy W&C rCy|4 2=-k3n
v@=mRDAmY@X
?GGYJfJ
v@=mRDAmY@X
V# T&NN
v@=mRDAmY@X
kf gh(GG
v@=mRDAmY@X
j4 jY](]ᵃ
v@=mRDAmY@X
u7zJNfZ ma5`5ᵃ
v@=mRDAmY@X
iX0 T_[5[ᵃ
v@=mRDAmY@X
^{ :rxXXᵃ
v@=mRDAmY@X
w! A^?C# LuV
v@=mRDAmY@X
~@ 6uHLR mF\
v@=mRDAmY@X
$p 4ch+3 ;9=J[=
v@=mRDAmY@X
B=dRm^zRl ~UU3 [`
v@=mRDAmY@X
a{Od5 O]$[9e
v@=mRDAmY@X
a{Od5 O]$[9e
v@=mRDAmY@X
a{Od5 O]$[9e
v@=mRDAmY@X
a{Od5 O]$[9e
v@=mRDAmY@X
a{Od5 O]$[9e
v@=mRDAmY@X
a{Od5 O]$[9e
v@=mRDAmY@X
*3 =9} {2V~A( h{J_
v@=mRDAmY@X
OQ&+AdMQ 8uulyu! CdHCG$
v@=mRDAmY@X
K+ =_)_
v@=mRDAmY@X
u7CIcCcQ7Q z=K=r=cr=TK F/4+a+4+~Ru
v@=mRDAmY@X
1[_[i1i ^CzCFCLFC2z ;LJB-BJBNp_
v@=mRDAmY@X
gy; tNnN
v@=mRDAmY@X
/bZBb
v@=mRDAmY@X
lt}*vjZ** 2W2 /:qK?? ,JqJcJvcJdq gzG]]]G]\{9
v@=mRDAmY@X
S@E;2Z 61o C:bob)bs ylQyN5

O% pf [Py DSDJ

)Ensem collaboration; BeiGene has global rights. &DualityBio collaboration; BeiGene has global rights. /Leads Biolabs collaboration; BeiGene has ex-China commercial rights. dMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. cZymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. 7Amgen collaboration; BeiGene has China commercial rights. ;Luye collaboration; BeiGene has China rights. L in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login